Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 272 of 6351
-
Can splitting radiation save more hearing in acoustic neuroma patients?
Disease control CompletedMost vestibular schwannomas are benign and slow-growing. Based on that fact, conservative management with serial imaging is a viable alternative. For patients who undergo treatment because of tumor growth, progressive symptoms, or personal preference, options include serial obser…
Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Can sound waves replace the scalpel for breast cancer?
Disease control CompletedThe goal of this prospective, non-randomized, single-arm, multi site, international study is to develop data to evaluate the safety and effectiveness of the ExAblate MRgFUS system in the ablation of breast cancer and of MRI. The goal of MRgFUS ablation of breast cancer is to pla…
Phase 2 • Sponsor: InSightec • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Stem cell transplant vs. drugs: which works better for younger myeloma patients?
Disease control CompletedObjective of this study is to determine if, in the era of novel drugs, high dose therapy (HDT) is still necessary in the initial management of multiple myeloma in younger patients. HDT as compared to conventional dose treatment would be considered superior if it significantly pro…
Phase 3 • Sponsor: University Hospital, Toulouse • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Peanut allergy patch: a new hope for kids?
Disease control CompletedThis study aims at showing that Epicutaneous Immunotherapy with peanut proteins is safe and efficacious for desensitizing children with peanut allergy.
Phase 2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can a smart drug missile tame Hard-to-Treat leukemia?
Disease control CompletedThe goal of this clinical research study is to learn if CMC-544 given alone, and possibly given in combination with rituximab, can help to control the disease in patients with ALL. The safety of the study drug(s) will also be studied.
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
Could extra chemo beat brain tumors in kids?
Disease control CompletedThe primary aim of this randomized phase III trial was to study whether the addition of maintenance chemotherapy delivered after surgical resection and focal radiation would be better than surgery and focal radiation alone. The trial also studied if patients who received inductio…
Phase 3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New antibody combo shows promise in tough childhood cancer
Disease control CompletedThis phase III trial is studying the side effects of giving monoclonal antibody Ch14.18 together with sargramostim, aldesleukin, and isotretinoin after autologous stem cell transplant in treating patients with neuroblastoma. Monoclonal antibodies, such as Ch14.18, may find tumor …
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New pill could slow worsening of rare lung disease
Disease control CompletedThe AC-065A302 (GRIPHON) study is an event-driven Phase 3 study to demonstrate the effect of selexipag on time to first morbidity or mortality event in patients with pulmonary arterial hypertension.
Phase 3 • Sponsor: Actelion • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New combo attack on leukemia: chemo plus targeted drug shows promise
Disease control OngoingThis phase II trial is studying the side effects of giving combination chemotherapy together with or without donor stem cell transplant and to see how well it works in treating patients with acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop t…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Can a new oral drug outsmart Radioiodine-Resistant thyroid cancer?
Disease control CompletedSince thyroid cancer becomes refractory to radioactive iodine, treatment options are very limited. Tyrosine kinase inhibitors such as sorafenib have recently shown promise. This trial seeks to expand treatment options for this disease with a new, oral drug called RAD001. It is an…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a Two-Drug combo outsmart returning childhood cancers?
Disease control CompletedThe purpose of the study is to determine whether the combination of Hycamtin (Topotecan) and Temozolomide is effective in the treatment of relapsed and refractory neuroblastoma and other paediatric solid tumors.
Phase 2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
MRI-Guided radiation: a sharper weapon against prostate cancer?
Disease control Recruiting nowThis pilot study initiates a research program testing the early technical and clinical performance of a novel procedure for MRI-guided high-dose-rate (HDR) prostate brachytherapy. Testing will proceed in two cohorts of patients. In Arm 1, patients with locally recurrent prostate …
Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Could a lower dose of an old antibiotic tame Drug-Resistant TB?
Disease control CompletedThis study evaluated the safety and tolerability of low-dose linezolid (600 mg once daily) administered for 16 weeks as part of an optimized background regimen for the treatment of multidrug-resistant tuberculosis (MDR-TB).
Phase 1/2 • Sponsor: Centers for Disease Control and Prevention • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New pill shrinks tough skin cancers in early trial
Disease control CompletedThis is a Phase II, single-arm, two-cohort multicenter clinical trial evaluating the efficacy and safety of vismodegib (GDC-0449) in patients with advanced basal cell carcinoma. All patients receive vismodegib until evidence of progression, intolerable toxicities most probably at…
Phase 2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Engineered t cells with a kill switch aim to make stem cell transplants safer
Disease control OngoingPatients are being asked to participate in this study because they will be receiving a stem cell transplant as treatment for their disease. As part of the stem cell transplant, they will be given very strong doses of chemotherapy, which will kill off all their existing stem cells…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New hope for hepatitis c: triple therapy shows promise in untreated patients
Disease control CompletedThis study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b (PEG-IFN) and Ribavirin (RBV) in treatment-naïve patients with (Genotype 1) hepatitis C.
Phase 3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New hope for hepatitis c relapsers: triple therapy shows promise
Disease control CompletedThis study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b (PEG-IFN) and Ribavirin (RBV) in patients with (Genotype 1) hepatitis C, who relapsed after previous treatment.
Phase 3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Can a stronger radiation blast beat aggressive prostate cancer?
Disease control OngoingRATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. It is not yet known which dose of radiation thera…
Sponsor: UNICANCER • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Lab-grown stem cells may restore damaged eye surfaces
Disease control CompletedThe purpose of this study is to determine whether cultivated stem cell transplantation is effective for the treatment of patients wtih corneal stem cell deficiency.
Sponsor: Veerle Van Gerwen • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Lung cancer drug shows promise in keeping tumors at bay after chemo
Disease control CompletedThis randomized phase III trial studies sunitinib malate to see how well it works when given as maintenance therapy (meaning it is approved for treatment after chemotherapy) in patients with stage IIIB-IV non-small cell lung cancer who have responded to prior treatment with combi…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC